JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 18, 2006; DOI: 10.1124/jpet.105.096867


0022-3565/06/3172-590-597$20.00
JPET 317:590-597, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.096867v1
317/2/590    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mesia-Vela, S.
Right arrow Articles by Kauffman, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mesia-Vela, S.
Right arrow Articles by Kauffman, F. C.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Phenobarbital Treatment Inhibits the Formation of Estradiol-Dependent Mammary Tumors in the August-Copenhagen Irish Rat

Sonia Mesia-Vela, Rosa I. Sanchez, Kenneth R. Reuhl, Allan H. Conney, and Frederick C. Kauffman

Laboratory for Cellular and Biochemical Toxicology (S.M.-V., R.I.S., F.C.K.), Laboratory for Neurotoxicology (K.R.R.), Department of Pharmacology and Toxicology, and Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology (A.H.C.), Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey

Exposure of female August-Copenhagen Irish (ACI) rats for 28 weeks to 3 mg of estradiol (E2) contained in cholesterol pellets elevated blood E2 levels and caused palpable mammary tumors in all animals. Coadministration of phenobarbital (PB) in their drinking water reduced the incidence, number, and size of mammary tumors (MTs) but did not reduce blood E2 levels. Inhibition of MTs by PB was accompanied by significant changes in total hepatic metabolism of E2 measured in vitro. PB treatment caused approximately a 4-fold increase in hepatic metabolism of E2 in control and E2-treated rats. The major NAD(P)H-dependent metabolites of E2 were 2-OH-E2 and estrone (E1). PB, either alone or together with E2, increased microsomal 2-hydroxylation of E2; formation of E1 was either unaffected or decreased slightly. PB also increased microsomal metabolism of E2 to minor metabolites (4-OH-E2, 6{alpha}-OH-E2, 6beta-OH-E2, 14{alpha}-OH-E2, 6-keto E1, and 2-OH-E1) and reduced the formation of the E2-17beta-oleoyl ester and the E2 3- and 17-glucuronides. In contrast, when given in combination with E2, PB increased the formation of both glucuronides. Cotreatment of animals with PB and E2 increased activities of NAD(P)H:quinone oxidoreductase and glutathione S-transferase to a greater extent than either compound alone. Collectively, these results show that the multiple actions of PB on hepatic metabolism of E2, including induction of E2 hydroxylation, glucuronidation, and antioxidant defense enzymes along with inhibition of E2 esterification in livers of female ACI rats, accompany a marked reduction of E2-dependent mammary tumors in this model.


Received for publication October 13, 2005
Accepted January 17, 2006.

Address correspondence to: Dr. Frederick C. Kauffman, Rutgers University, 41 Gordon Rd., Piscataway, NJ 08854. E-mail: kauffma{at}rci.rutgers.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.